Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LYRA NASDAQ:NEPH NASDAQ:NMTC NASDAQ:WOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLYRALyra Therapeutics$6.35+0.3%$7.49$3.81▼$37.50$10.41M0.17263,860 shs62,166 shsNEPHNephros$4.27+1.4%$3.82$1.36▼$5.00$44.41M1.2328,974 shs26,270 shsNMTCNeuroOne Medical Technologies$0.89-0.5%$0.80$0.40▼$1.39$44.25M0.68273,279 shs430,329 shsWOKWORK Medical Technology Group$0.80-0.2%$0.79$0.36▼$8.45$45.60MN/A1.23 million shs10,074 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLYRALyra Therapeutics-1.25%-10.09%-6.22%-44.18%-52.83%NEPHNephros-1.41%+5.51%-1.17%+8.79%+123.34%NMTCNeuroOne Medical Technologies+0.71%+22.36%+12.36%+59.13%+10.41%WOKWORK Medical Technology Group-0.25%+2.31%+2.31%+1.01%-83.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLYRALyra Therapeutics$6.35+0.3%$7.49$3.81▼$37.50$10.41M0.17263,860 shs62,166 shsNEPHNephros$4.27+1.4%$3.82$1.36▼$5.00$44.41M1.2328,974 shs26,270 shsNMTCNeuroOne Medical Technologies$0.89-0.5%$0.80$0.40▼$1.39$44.25M0.68273,279 shs430,329 shsWOKWORK Medical Technology Group$0.80-0.2%$0.79$0.36▼$8.45$45.60MN/A1.23 million shs10,074 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLYRALyra Therapeutics-1.25%-10.09%-6.22%-44.18%-52.83%NEPHNephros-1.41%+5.51%-1.17%+8.79%+123.34%NMTCNeuroOne Medical Technologies+0.71%+22.36%+12.36%+59.13%+10.41%WOKWORK Medical Technology Group-0.25%+2.31%+2.31%+1.01%-83.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLYRALyra Therapeutics 2.00Hold$100.001,474.80% UpsideNEPHNephros 3.00Buy$5.5028.81% UpsideNMTCNeuroOne Medical Technologies 3.00Buy$2.23150.00% UpsideWOKWORK Medical Technology Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LYRA, WOK, NEPH, and NMTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025NMTCNeuroOne Medical TechnologiesMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$3.008/14/2025LYRALyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral8/8/2025NEPHNephrosMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$4.50 ➝ $6.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLYRALyra Therapeutics$1.53M6.81N/AN/A$8.86 per share0.72NEPHNephros$14.16M3.20$0.02 per share213.38$0.81 per share5.27NMTCNeuroOne Medical Technologies$3.45M12.90N/AN/A$0.03 per share29.67WOKWORK Medical Technology Group$11.51M3.96N/AN/A$1.10 per share0.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLYRALyra Therapeutics-$93.43M-$29.01N/AN/AN/A-5,043.64%-404.56%-60.06%11/11/2025 (Estimated)NEPHNephros$70K$0.1234.92∞N/A7.95%14.89%11.64%11/6/2025 (Estimated)NMTCNeuroOne Medical Technologies-$12.32M-$0.15N/A∞N/A-55.44%-163.49%-78.67%N/AWOKWORK Medical Technology Group-$3.49MN/A0.00∞N/AN/AN/AN/AN/ALatest LYRA, WOK, NEPH, and NMTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q3 2025NMTCNeuroOne Medical Technologies-$0.05-$0.03+$0.02-$0.03$1.82 million$1.70 million8/12/2025Q2 2025LYRALyra Therapeutics-$5.79-$5.51+$0.28-$5.51$0.18 million$0.29 million8/7/2025Q2 2025NEPHNephros-$0.0250$0.02+$0.0450$0.02$3.60 million$4.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLYRALyra TherapeuticsN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/ANMTCNeuroOne Medical TechnologiesN/AN/AN/AN/AN/AWOKWORK Medical Technology GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLYRALyra TherapeuticsN/A2.782.78NEPHNephrosN/A5.414.14NMTCNeuroOne Medical TechnologiesN/A7.135.80WOKWORK Medical Technology GroupN/A1.140.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLYRALyra Therapeutics95.62%NEPHNephros41.10%NMTCNeuroOne Medical Technologies16.07%WOKWORK Medical Technology GroupN/AInsider OwnershipCompanyInsider OwnershipLYRALyra Therapeutics3.25%NEPHNephros6.70%NMTCNeuroOne Medical Technologies8.90%WOKWORK Medical Technology GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLYRALyra Therapeutics501.64 million1.59 millionOptionableNEPHNephros3010.60 million9.89 millionNot OptionableNMTCNeuroOne Medical Technologies2050.00 million45.55 millionOptionableWOKWORK Medical Technology Group22657.00 millionN/AN/ALYRA, WOK, NEPH, and NMTC HeadlinesRecent News About These CompaniesUnivest Securities, LLC Announces Closing of $5 Million Registered Offering for its Client WORK Medical Technology Group LTD (NASDAQ: WOK)May 22, 2025 | globenewswire.comWORK Medical Technology Group LTD Announces Closing of Registered OfferingMay 22, 2025 | globenewswire.comWORK Medical Technology Group LTD Announces Pricing of Registered OfferingMay 21, 2025 | globenewswire.comWORK Medical Technology Group LTD Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyApril 11, 2025 | globenewswire.comWORK Medical Technology Group LTD Announces Implementation of Dual-Class Share Structure Effective March 6, 2025March 5, 2025 | globenewswire.comWORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.February 28, 2025 | globenewswire.comWORK Medical Technology Group LTD Reports Financial Results for Fiscal Year 2024February 14, 2025 | prnewswire.comWORK Medical Technology Group LTD's Subsidiary, Hangzhou Shanyou, Showcases Products at MEDICA Trade Fair 2024November 27, 2024 | globenewswire.comWORK Medical Technology Group LTD Announces Partial Exercise of Underwriters' Over-Allotment OptionAugust 29, 2024 | globenewswire.comWORK Medical Technology Group LTD Announces Closing of Initial Public OfferingAugust 26, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLYRA, WOK, NEPH, and NMTC Company DescriptionsLyra Therapeutics NASDAQ:LYRA$6.32 -0.01 (-0.08%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Nephros NASDAQ:NEPH$4.22 +0.01 (+0.14%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.NeuroOne Medical Technologies NASDAQ:NMTC$0.89 0.00 (-0.15%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.WORK Medical Technology Group NASDAQ:WOK$0.80 0.00 (-0.16%) As of 02:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.WORK Medical Technology Group Ltd. engages in developing health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
